Patents by Inventor Bruce S. Thalley

Bruce S. Thalley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Soluble recombinant botulinum toxin proteins
    Patent number: 6967088
    Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.
    Type: Grant
    Filed: August 28, 1996
    Date of Patent: November 22, 2005
    Assignees: Allergan, Inc., Allergan Botox Limited
    Inventors: James A. Williams, Bruce S. Thalley
  • Soluble recombinant botulinum toxin proteins
    Publication number: 20030215468
    Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.
    Type: Application
    Filed: January 30, 2003
    Publication date: November 20, 2003
    Applicant: Allergan, Inc., Allergan Botox Limited
    Inventors: James A. Williams, Bruce S. Thalley
  • Vaccine and antitoxin for the treatment of C. difficile disease
    Patent number: 6290960
    Abstract: The present investion provides vaccines capable of protecting a vaccinated recipient from the morbidity and mortality associated with C. difficile infection. These vaccines are produced with portions of C. difficile Toxin A, or Toxin B, or both. These portions of Toxins A and B may be fusion proteins with at least one non-toxin protein sequence, and may also be soluble and substantially endotoxin-free. These vaccines are useful for administration to humans and other animals at risk of exposure to C. difficile toxins.
    Type: Grant
    Filed: August 20, 1997
    Date of Patent: September 18, 2001
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventors: John A. Kink, Bruce S. Thalley, Douglas C. Stafford
  • Treatment of Clostridium difficile induced disease
    Patent number: 5736139
    Abstract: The present provides neutralizing antitoxin directed against C. difficile toxins. These antitoxins are produced in arian species using soluble recombinant C. difficile toxin proteins. The avian antitoxins are designed so as to be orally administrable in therapeutic amounts and may be in any form (i.e., as a solid or in aqueous solution). Solid forms of the antitoxin may comprise an enteric coating. These antitoxins are useful in the treatment of humans and other animals intoxicated with at least one bacterial toxin. The invention further provides vaccines capable of protecting a vaccinated recipient from the morbidity and mortality associated with C. difficile infection. These vaccines are useful for administration to humans and other animals at risk of exposure to C. difficile toxins.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 7, 1998
    Assignee: Ochidian Pharmaceuticals, Inc.
    Inventors: John A. Kink, Bruce S. Thalley, Douglas C. Stafford, Joseph R. Firca, Nisha V. Padhye